Edition:
United States

Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

66.88USD
19 Oct 2018
Change (% chg)

$0.06 (+0.09%)
Prev Close
$66.82
Open
$67.23
Day's High
$68.07
Day's Low
$65.75
Volume
581,275
Avg. Vol
144,011
52-wk High
$99.77
52-wk Low
$51.66

Chart for

About

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are... (more)

Overall

Beta: 2.02
Market Cap(Mil.): $3,949.29
Shares Outstanding(Mil.): 57.99
Dividend: --
Yield (%): --

Financials

  AGIO.OQ Industry Sector
P/E (TTM): -- 119.85 32.14
EPS (TTM): -6.22 -- --
ROI: -41.13 1.96 12.83
ROE: -48.79 1.12 14.95

Agios names former Celgene executive Jacqualyn Fouse as next CEO

Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

Sep 04 2018

UPDATE 1-Agios names former Celgene executive Jacqualyn Fouse as next CEO

Sept 4 Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

Sep 04 2018

Agios names former Celgene executive Jacqualyn Fouse as next CEO

Sept 4 Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

Sep 04 2018

Agios Pharmaceuticals leukemia drug gets U.S. approval

Agios Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration approved its treatment for a type of leukemia, the first targeted drug for patients with a specific genetic mutation.

Jul 20 2018

UPDATE 1-Agios Pharmaceuticals leukemia drug gets U.S. approval

July 20 Agios Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration approved its treatment for a type of leukemia, the first targeted drug for patients with a specific genetic mutation.

Jul 20 2018

FDA approves Agios Pharmaceuticals leukemia drug

July 20 Agios Pharmaceuticals Inc said on Friday its oral drug to treat a type of leukemia was approved by the U.S. health regulator.

Jul 20 2018

BRIEF-Agios Qtrly Loss Per Share $1.63

* AGIOS PROVIDES BUSINESS UPDATE ON DISCOVERY RESEARCH STRATEGY AND PIPELINE, PROGRESS ON CLINICAL PROGRAMS, COMMERCIAL LAUNCH PREPARATIONS AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AT INVESTOR DAY

May 04 2018

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $44.50 +0.50
Novartis AG (NOVN.S) CHF87.04 +1.16
Roche Holding Ltd. (ROG.S) CHF244.95 +6.40
Roche Holding Ltd. (RO.S) CHF245.20 +5.80
Sanofi SA (SASY.PA) €77.80 0.00
AstraZeneca plc (AZN.L) 5,934.00 +56.00
GlaxoSmithKline plc (GSK.L) 1,557.60 +47.00
Eli Lilly And Co (LLY.N) $111.92 -1.39
Shire PLC (SHP.L) 4,508.00 -13.00
Shire PLC (3159084.L) -- --

Earnings vs. Estimates